Objectives: To determine the incidence and age-related fracture risk among HIV-infected (HIV+) and uninfected men (HIV-). To evaluate factors independently associated with fracture risk.
INTRODUCTION
Osteopenia and osteoporosis are more prevalent in HIV+ men and women compared with HIV-controls (1) and young HIV+ individuals are also at higher risk of bone loss (2, 3, 4) .
Low bone mineral density (BMD) translates into a higher risk of fracture (5, 6 ) which is higher is HIV+ individuals. Triant et al. reported higher prevalence of vertebral, hip and wrist fractures in HIV+ men and higher prevalence of vertebral and wrist fractures in HIV+ women compared to HIV-controls (7) . Higher rates of fracture in young HIV+ men have been previously reported (3, 7) while studies in young HIV+ women have shown conflicting results (8, 9) . Among HIV+ patients, several risk factors have been associated with bone loss and higher incidence of fracture, including traditional risk factors such as age, sex, race, body mass index (BMI), smoking, alcohol and drug use (10, 11) , HIV-specific factors (3, 12, 13, 14, 15) and specific antiretroviral therapy (ART) agents, especially protease inhibitors (PI) and tenofovir disoproxil fumarate (TDF) containing combinations (15, 16, 17, 18) . Coinfection with hepatitis C virus (HCV) increased fracture risk in several reports (3), while others found no association (9) .
Early screening for fracture risk in HIV+ individuals has been recommended (19, 20) but the exact age when screening should start remains controversial. There is still extensive variation in the approach to screening for osteoporosis in HIV+, not only in the USA but also worldwide (21). men who were 40 years or older and had one additional visit were considered eligible for this study. The first MACS visit at which an individual came under observation for fracture outcomes was designated the index visit. HIV+ participants who never received ART before they were last seen in the MACS by March 2015 were excluded. The final study population included 2629 men.
Outcome: Incident fracture
In this study, we considered two self-reported fracture outcomes that occurred among men of 40 years and over: 1) all fractures except for those occurring at the face, skull or digits and 2) fragility fractures, defined as fractures at vertebral column, femur, wrist and humerus (26).
Exposure of interest: Age and HIV
Self-reported date of birth was obtained at enrollment into the MACS. HIV seropositivity was determined using an enzyme-linked immunosorbent assay (ELISA) confirmed by Western blot. Standardized tests were used for measuring CD4+ T lymphocyte counts (cells/microliter 3 ) (CD4+) and plasma HIV-1 RNA concentrations.
Confounders:
Race was obtained at enrollment into the MACS. Self-reported cigarette smoking and alcohol use, BMI, co-morbidities, T lymphocyte counts (cells/microliter 3 )(CD4 + ) and plasma HIV-1 RNA concentrations were assessed at each semi-annual visit. Estimated glomerular filtration rate (eGFR) in mL/min/1.73m RNA levels. Diabetes mellitus was defined as a fasting glucose ≥126 mg/dL or a selfreported diabetes diagnosis with the use of glucose-lowering medications. High blood pressure was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or self-reported diagnosis with use of anti-hypertensive medication. Viremia copy-years (VCY) was calculated as the area under the viral load curve from the index visit or the first available viral load after seroconversion, whichever occurred later, by applying the trapezoidal rule (27). Other HIV-specific factors that were considered include the history of AIDS diagnosis, any ART use, and cumulative use of TDF and PI per 5 years.
Statistical analyses
Demographic and clinical characteristics at the index visit were compared by HIV serostatus using Wilcoxon rank-sum test for continuous variables and (Table 2) . When current HIV-1 RNA > 400 copies/mL was replaced by VCY in the multivariable model, higher VCY was associated with all fractures (IRR 1.14 per log10 increase in VCY (1.01, 1.30); p=0.042) ( Table 4 supplementary, http://links.lww.com/QAD/B83). Neither cumulative TDF use, nor cumulative PI use was associated with a higher rate of all fractures ( Table 2 ). The unadjusted risk of fragility fracture is shown in Table 3 Table 2 ). Neither HIV-1 RNA > 400 copies/mL nor VCY were associated with higher incidence of fragility fractures ( Table 2 and Table 4 (supplementary, http://links.lww.com/QAD/B83)). Cumulative PI use and cumulative TDF use were not associated with incident fragility fracture.
Incidence of fragility fractures

DISCUSSION:
In this cohort of MSM we found that the fracture incidence increased with older age among both the HIV+ and HIV-participants, however, the fracture rate was higher in Virtual Cohort (VACS-VC) there was a significant increase in the risk of fragility fracture with advancing age (HR 1.52 per 10 year increments) even after adjustment for multiple factors (11) . In our analysis, we found an increase in the incidence of all fractures and fragility fractures among HIV+ men starting at age 50. The fracture incidence rates we observed in MACS are somewhat different from those reported by others. In the Danish population, Hansen at al reported a fracture incidence of 21 per 1000 PY in the HIV+ and 13.5 per 1000 PY in the HIV-. The incidence of fragility fracture among male veterans from VACS-VC was slightly lower, with 2.5 per 1000 PY for HIV+ and 1.9 per 1000 PY for HIV-persons. It is possible that our study population is unique in several aspects. Additionally, the HIV-comparison group in the MACS are drawn from a population of MSM with very similar underlying risk factors to the HIV+ men, which is a major strength of our study.
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Amongst several risk factors investigated, we found that hypertension was an independent predictor of all fractures with similar trends for the outcome of fragility fracture. Although data are sparse, there is some clinical evidence, mainly from observational studies, supporting an increased fracture risk in hypertensive people. While some studies found only an increased risk of vertebral fractures in hypertensive patients (30), others demonstrated a higher risk of any fracture (31). An observational cohort study of Australians aged 50 years and above, found hypertension to be associated with an increased risk of fragility fractures in women but not in men (32). While the exact underlying mechanism remains uncertain, several potential explanations for the effect of hypertension on fracture risk exist. High blood pressure has been associated with increased urinary calcium loss, secondary hyperparathyroidism and loss of calcium from bone (33) . In addition, hypertensive patients tend to be older and more prone to falls (34) .
Furthermore, antihypertensive medications, apart from increasing the risk of fall injuries by causing or worsening orthostatic hypotension (35) , may also exert direct effects on bone (36) . Data on falls, frailty and markers of calcium metabolism were not available for the entire period covered by this analysis, therefore we could not assess potential mechanisms for the observed hypertension/fracture association.
Low eGFR has been associated with increased fracture risk (37) . In our study, eGFR was no longer associated with fractures after adjusting for age, BMI and hypertension. This finding suggests that the association of eGFR and fracture may be due to other confounders or that the lack of an association was due to the small number of participants with moderate and severe kidney impairment in our study population. Several studies Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
evaluating the association between chronic kidney disease (CKD) and fractures have reported increased fracture risk only with moderate to severe CKD (38) .
We found no associations between the incidence of fractures and other factors like BMI, race, current smoking, moderate-heavy or binge alcohol consumption, diabetes or HCV.
Several studies have reported significantly higher rates of fractures in patients with HIV and HCV co-infection compared to those with HIV mono-infection (3, 39) , while others have not reproduced this finding (9) . HCV has been shown to be a marker of intravenous drug use (40) and the higher risk of fracture in HIV-HCV co-infected patients has thus been attributed to direct consequences of drug use such as higher risk of trauma, falls and nutritional deficiencies (17) . The small percentage of MACS participants reporting use of intravenous drugs (2%) might explain why no association was detected in our analysis.
The role of HIV specific factors in fracture risk remains uncertain. While no association with ART exposure have been reported in several studies (3, 9) , others found higher rates of fractures associated with ART exposure (11, 17) . Using data from the ACTG Longitudinal-Linked Randomized Trial (ALLRT), Yin et al. found a significantly higher fracture rate in the first 2 years after ART initiation that declined in subsequent years (41) . We found that current ART use was associated with an increased risk of fracture.
These findings are consistent with results from the Strategies for Management of Antiretroviral Therapy (SMART) sub-study in which continuous administration of ART results in losses in BMD, whereas ART interruption was associated with BMD stabilization or increases. (16) . Taken together these findings suggest that ART treatment, regardless of the ART regimens used has detrimental effects on bone health. Specific ART medications, including TDF and PIs have been associated with loss of BMD and increased fracture risk in some (11, 18) (42), but not all studies (9) . In our multivariate analysis, neither cumulative PI use, nor TDF was associated with increased incidence of all or fragility fractures, although our study was not specifically designed to assess effects of specific medications, in that the relatively small number of events may have limited the statistical power to detect associations.
We found no associations between CD4+ T-cell count and history of AIDS with fracture risk. While some studies have reported increased fracture rates in individuals with low CD4+ T-cell count (3) and a history of AIDS-defining illness, others have not (17, 42) .
We did, however, find an association between cumulative viremia and fracture independent of receiving ART. This finding suggests that the legacy of poorly controlled HIV infection in the past may have important future clinical consequences with respect to fracture risk and that patients who have a long history of uncontrolled viremia may benefit from more aggressive osteoporosis screening and treatment.
Our study has several strengths including a relatively large sample size, incidence of all fractures and fragility fractures as main outcomes and data on several fracture risk factors. Additionally, the MACS includes HIV-men with similar risk behaviors as the HIV+ and regardless of HIV serostatus, men were followed semiannually and completed the same fracture questionnaires. We performed risk analyses stratified by age and HIV serostatus allowing us to demonstrate age strata specific increases in fracture rates.
Furthermore, data on HIV specific risk factors were collected at semiannual visits.
We also recognize several limitations. Fractures were self-reported without confirmation by medical chart review or radiographic evaluation although fractures are adverse events Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
that patients tend to remember and reliably self-report (43) . We were not able to determine specifically whether fractures occurred in the setting of major trauma, which might have resulted in the overestimation of fragility fractures. Additionally, since histories of fractures were retrospectively collected through questionnaires, recollection bias might be an important limitation. Furthermore, we have no data on calcium and vitamin D supplementation and we did not account for drugs that may have an impact on bone health, such as the proton pump inhibitors. Specific information on testosterone and glucocorticoid use was introduced in the MACS questionnaire only recently. Missing data was an issue particularly for variables only later routinely collected in the MACS but we addressed this limitation by using multiple imputation analysis to fill in missing covariates data.
In conclusion, we found that HIV+ MACS participants had higher incidence of all fractures and fragility fractures compared to the HIV-controls and that the rate of fracture was higher among the HIV+ men aged 50-59 years compared with HIVparticipants of similar age. Our findings support the current available guidelines recommending baseline DXA screening for HIV+ men starting at age 50. Hypertension remained consistently associated with higher incidence of all fractures even after adjustment for additional fracture risks. To our knowledge, this is the first report in which an association between hypertension and increased fracture incidence among HIV+ persons has been noted. The exact mechanism underlying the association between BMD, fracture, hypertension and antihypertensive agents remains largely unknown and warrants further exploration.
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